OBJECTIVES: To study the prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor VEGFR-1 in localized prostate cancer. METHODS: One hundred patients undergoing radical prostatectomy (RP) for clinically localized prostate cancer were prospectively included. Plasma levels of VEGF-A were measured preoperatively. After intervention, tissue microarrays were built from the RP specimens. VEGF-A and VEGFR-1 expressions in prostate cancer tissue were determined using immunochemistry. Then the associations between plasma levels of VEGF-A, VEGF-A and VEGFR-1 expressions in prostate cancer tissue, and the outcome of patients were analyzed. RESULTS: After a median follow-up of 22 months, 14 patients experienced biological recurrence of prostate cancer. There was no correlation between plasma VEGF-A and the risk of recurrence following RP. Moreover, there was no correlation between VEGF-A expression or VEGFR-1 expression in prostate cancer tissue and the risk of recurrence after RP. CONCLUSIONS: Plasma levels of VEGF-A, the expression of VEGF-A and that of VEGFR-1 in prostate cancer tissue did not affect patients outcome following RP. VEGF-A and its receptor VEGFR-1 may have no prognostic value in localized prostate cancer. Further studies with longer follow-up are mandatory to confirm these findings.
OBJECTIVES: To study the prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor VEGFR-1 in localized prostate cancer. METHODS: One hundred patients undergoing radical prostatectomy (RP) for clinically localized prostate cancer were prospectively included. Plasma levels of VEGF-A were measured preoperatively. After intervention, tissue microarrays were built from the RP specimens. VEGF-A and VEGFR-1 expressions in prostate cancer tissue were determined using immunochemistry. Then the associations between plasma levels of VEGF-A, VEGF-A and VEGFR-1 expressions in prostate cancer tissue, and the outcome of patients were analyzed. RESULTS: After a median follow-up of 22 months, 14 patients experienced biological recurrence of prostate cancer. There was no correlation between plasma VEGF-A and the risk of recurrence following RP. Moreover, there was no correlation between VEGF-A expression or VEGFR-1 expression in prostate cancer tissue and the risk of recurrence after RP. CONCLUSIONS: Plasma levels of VEGF-A, the expression of VEGF-A and that of VEGFR-1 in prostate cancer tissue did not affect patients outcome following RP. VEGF-A and its receptor VEGFR-1 may have no prognostic value in localized prostate cancer. Further studies with longer follow-up are mandatory to confirm these findings.
Authors: Jianqing Lin; Tingting Zhan; Danielle Duffy; Jean Hoffman-Censits; Deborah Kilpatrick; Edouard J Trabulsi; Costas D Lallas; Inna Chervoneva; Kimberly Limentani; Brooke Kennedy; Sarah Kessler; Leonard Gomella; Emmanuel S Antonarakis; Michael A Carducci; Thomas Force; Wm Kevin Kelly Journal: Am J Cancer Ther Pharmacol Date: 2014-09-07
Authors: Silvan Boxler; Valentin Djonov; Thomas M Kessler; Ruslan Hlushchuk; Lucas M Bachmann; Ulrike Held; Regula Markwalder; George N Thalmann Journal: Am J Pathol Date: 2010-10-01 Impact factor: 4.307
Authors: Anna Gasinska; Janusz Jaszczynski; Urszula Rychlik; Elżbieta Łuczynska; Marek Pogodzinski; Mikolaj Palaczynski Journal: Pathol Oncol Res Date: 2019-04-15 Impact factor: 3.201
Authors: Maxim Rybalov; Hildo J K Ananias; Hilde D Hoving; Henk G van der Poel; Stefano Rosati; Igle J de Jong Journal: Int J Mol Sci Date: 2014-04-10 Impact factor: 5.923
Authors: Josué Rivera-Pérez; María Del Rocío Monter-Vera; Cornelio Barrientos-Alvarado; Julia D Toscano-Garibay; Teresa Cuesta-Mejías; Javier Flores-Estrada Journal: Oncol Lett Date: 2017-11-08 Impact factor: 2.967